Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and ...
Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock ...
J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and ...
Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...
Hosted on MSN
Down 80%, should you buy the dip on Moderna?
Moderna’s earnings and stock price climbed during early pandemic days -- that’s as demand for the company’s coronavirus vaccine soared. Since, the company has faced various challenges that have ...
Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine ...
Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...
Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications. As Kevin Warsh steps up to lead the Federal Reserve, the case for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results